Alzheimer, also known as dementia, is a progressive disorder that weakens the brain cells and eventually results in the death of the patient. There are no specific drugs known to cure these kinds of patients, but the medications can stop the progression of the disease or help to ease the symptoms for some time. However, for the underlying disease of the brain, these drugs cannot stop or slow the progression. Some of the drugs approved by FDA to control Alzheimer's disease include Memantine and Cholinesterase inhibitors. Memantine regulates the activities of glumate, which is widely engaged in brain activity for the functioning of memory and learning, while cholinesterase inhibitors boost the acetylcholine, present for nerve cells by avoiding its break in the brain.
Market Industry Reports (MIR) has published a new report titled "Global Alzheimers Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report, the global Alzheimers Drugs market was estimated to be over US $ 3.5 Bn in 2018. It is anticipated to grow at a CAGR of 7.2% from 2019 to 2030.Major Key Players of the Alzheimer's Drugs Market are:
AC Immune, F. Hoffmann-La Roche, DAIICHI SANKYO COMPANY, Eli Lilly and Company, H. Lundbeck A/S, Eisai Co., Avanir Pharmaceuticals, Inc., Novartis AG, Janssen Global Services, LLC, AbbVie Inc. among others.
No comments:
Post a Comment